| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8f5dfc0eed1db83b989cce292d784356 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70532 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0056
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-08 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-08 |
| filingDate |
2019-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f34a648e211b008b53630b298055652
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3c1a48522080da599734af6bc2ad3c72
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ee39b8d7a2394b195d5a110e21603ac4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_caf6e5969939a131828e22b75210ba9e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ddf264a2fb2244f80ae029cb500dcaa5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d8f3f76c1d8e212f5e6acab350bd3574 |
| publicationDate |
2020-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020128527-A1 |
| titleOfInvention |
Bicyclic peptide ligands specific for pd-l1 |
| abstract |
The present invention relates to polypeptides which are covalently bound to aromatic molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of PD-L1.The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by PD-L1. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022148979-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021019246-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022148975-A1 |
| priorityDate |
2018-12-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |